Comparative Pharmacology
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
EPANOVA vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis; electrolytes maintain acid-base balance and cellular function; dextrose provides caloric energy. Sulfite-free formulation reduces risk of allergic reactions.
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous infusion; dose determined by individual protein and caloric requirements, typically 1.5 to 2.5 g/kg/day of amino acids (equivalent to 35-59 mL/kg/day of TRAVASOL 4.25%) for adults.
None Documented
None Documented
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Amino acids: 0.5-2 hours; dextrose: 1-2 hours; clinical context: rapid elimination necessitates continuous infusion to maintain nutrient levels.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Renal excretion of amino acids and dextrose metabolites; virtually 100% renal elimination of infused water and electrolytes.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution